Literature DB >> 12207074

Influence of a human protease inhibitor on surgical stress induced immunosuppression.

Nobuhiro Sato1, Shigeatsu Endo, Yusuke Kimura, Kenichirou Ikeda, Kiichi Aoki, Takeshi Iwaya, Yuji Akiyama, Yoshinori Noda, Kazuyoshi Saito.   

Abstract

BACKGROUND/AIM: Postoperative tissue injury and immunosuppression can occur after major surgery. In this study, we explore the potential benefits of administering a protease inhibitor to treat immunosuppression caused by surgical stress.
METHODS: Sixteen patients with esophageal cancer were preoperatively allocated at random into two equal groups. A urinary trypsin inhibitor, ulinastatin (UTI), was intravenously administered to the treatment (UTI) group at a dose of 150,000 U every 12 h from the start of surgery until postoperative day 5, whereas the control group received a placebo. One unit of UTI was defined as the amount of UTI necessary to inhibit the activity of 2 microg of bovine pancreatic trypsin by 50%. We measured the plasma levels of polymorphonuclear neutrophil elastase, interleukin 8, circulating T lymphocyte subsets, and mitogenic activity and in vitro production of tumor necrosis factor alpha in lipopolysaccharide-stimulated whole blood.
RESULTS: The postoperative serum value of polymorphonuclear neutrophil elastase was significantly lower in the UTI group, but the interleukin 8 concentrations did not significantly vary between the two groups. On the other hand, the severity of the postoperative immunosuppression was reduced in the UTI group, and immune functions, such as the numbers of T lymphocytes, the mitogenic activity of lymphocytes, and the level of tumor necrosis factor alpha production in whole blood, recovered significantly earlier in the UTI group.
CONCLUSION: These data suggest that a protease-modulating therapy may be a new strategy for the treatment of surgical stress induced immune dysfunction. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12207074     DOI: 10.1159/000064578

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  10 in total

Review 1.  Effects of neutrophil elastase inhibitor in patients undergoing esophagectomy: a systematic review and meta-analysis.

Authors:  Zhi-Qiang Wang; Long-Qi Chen; Yong Yuan; Wen-Ping Wang; Zhong-Xi Niu; Yu-Shang Yang; Jie Cai
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 2.  High-mobility-group box chromosomal protein 1 as a new target for modulating stress response.

Authors:  Koichi Suda; Hiroya Takeuchi; Akitoshi Ishizaka; Yuko Kitagawa
Journal:  Surg Today       Date:  2010-06-26       Impact factor: 2.549

3.  Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis.

Authors:  Koichi Suda; Yuko Kitagawa; Soji Ozawa; Yoshiro Saikawa; Masakazu Ueda; Masahito Ebina; Shingo Yamada; Satoru Hashimoto; Shinji Fukata; Edward Abraham; Ikuro Maruyama; Masaki Kitajima; Akitoshi Ishizaka
Journal:  World J Surg       Date:  2006-09       Impact factor: 3.352

4.  Factors influencing difficulty of the thoracic procedure in minimally invasive esophagectomy.

Authors:  Akihiko Okamura; Masayuki Watanabe; Shinji Mine; Koujiro Nishida; Yu Imamura; Takanori Kurogochi; Yuko Kitagawa; Takeshi Sano
Journal:  Surg Endosc       Date:  2016-01-07       Impact factor: 4.584

5.  Protective effects of tumor necrosis factor alpha antibody and ulinastatin on liver ischemic reperfusion in rats.

Authors:  Yan-Ling Yang; Ji-Peng Li; Xiao-Ping Xu; Ke-Feng Dou; Shu-Qiang Yue; Kai-Zong Li
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

6.  Neutrophil elastase inhibitor (sivelestat) preserves antitumor immunity and reduces the inflammatory mediators associated with major surgery.

Authors:  Shintaro Akamoto; Keiichi Okano; Takanori Sano; Shinichi Yachida; Kunihiko Izuishi; Hisashi Usuki; Hisao Wakabayashi; Yasuyuki Suzuki
Journal:  Surg Today       Date:  2007-04-30       Impact factor: 2.549

7.  Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial.

Authors:  Cong-Yao Lin; De-Jiao Bai; Hong-Yin Yuan; Kun Wang; Guo-Liang Yang; Ming-Bai Hu; Zhou-Qing Wu; Yan Li
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

8.  Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: A randomized, double-blind, placebo-controlled, ascending-dose study.

Authors:  Qian Chen; Chaoying Hu; Ye Liu; Yun Liu; Wei Wang; Hongchao Zheng; Lianchen Rong; Jingying Jia; Shixuan Sun; Chen Yu; Yan Mei Liu
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

9.  Preventive effect of ulinastatin on postoperative complications, immunosuppression, and recurrence in esophagectomy patients.

Authors:  Lingmin Zhang; Ning Wang; Suna Zhou; Wenguang Ye; Qinglin Yao; Guixia Jing; Mingxin Zhang
Journal:  World J Surg Oncol       Date:  2013-04-10       Impact factor: 2.754

Review 10.  Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.

Authors:  Qiu-Lan He; Fei Zhong; Fang Ye; Ming Wei; Wei-Feng Liu; Mei-Na Li; Qiao-Bo Li; Wen-Qi Huang; Lai-Bao Sun; Hai-Hua Shu
Journal:  Biomed Res Int       Date:  2014-03-09       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.